RT Journal Article
SR Electronic
T1 RT-PCR/MALDI-TOF diagnostic target performance reflects circulating SARS-CoV-2 variant diversity in New York City
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.04.21267265
DO 10.1101/2021.12.04.21267265
A1 Hernandez, Matthew M.
A1 Banu, Radhika
A1 Gonzalez-Reiche, Ana S.
A1 Gray, Brandon
A1 Shrestha, Paras
A1 Cao, Liyong
A1 Chen, Feng
A1 Shi, Huanzhi
A1 Hanna, Ayman
A1 Ramírez, Juan David
A1 van de Guchte, Adriana
A1 Sebra, Robert
A1 Mount Sinai PSP Study Group
A1 Gitman, Melissa R.
A1 Nowak, Michael D.
A1 Cordon-Cardo, Carlos
A1 Schutzbank, Ted E.
A1 Simon, Viviana
A1 van Bakel, Harm
A1 Sordillo, Emilia Mia
A1 Paniz-Mondolfi, Alberto E.
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.04.21267265.abstract
AB As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate, multiple variants of concern (VOC) have emerged. New variants pose challenges for diagnostic platforms since sequence diversity can alter primer/probe binding sites (PBS), causing false-negative results. The Agena MassARRAY® SARS-CoV-2 Panel utilizes reverse-transcription polymerase chain reaction and mass-spectrometry to detect five multiplex targets across N and ORF1ab genes. Herein, we utilize a dataset of 256 SARS-CoV-2-positive specimens collected between April 11, 2021-August 28, 2021 to evaluate target performance with paired sequencing data. During this timeframe, two targets in the N gene (N2, N3) were subject to the greatest sequence diversity. In specimens with N3 dropout, 69% harbored the Alpha-specific A28095U polymorphism that introduces a 3’-mismatch to the N3 forward PBS and increases risk of target dropout relative to specimens with 28095A (relative risk (RR): 20.02; p<0.0001; 95% Confidence Interval (CI): 11.36-35.72). Furthermore, among specimens with N2 dropout, 90% harbored the Delta-specific G28916U polymorphism that creates a 3’-mismatch to the N2 probe PBS and increases target dropout risk (RR: 11.92; p<0.0001; 95% CI: 8.17-14.06). These findings highlight the robust capability of Agena MassARRAY® SARS-CoV-2 Panel target results to reveal circulating virus diversity and underscore the power of multi-target design to capture VOC.Competing Interest StatementRobert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai. Otherwise, the authors declare no competing interests.Funding StatementThe Research reported in this paper was supported by the National Institutes of Health (NIH) contract number HHSN272201400008C, the NIH Office of Research Infrastructure under award numbers S10OD018522 and S10OD026880, institutional and philanthropic funds (Open Philanthropy Project, #2020-215611), as well as a Robin Chemers Neustein Postdoctoral Fellowship Award (to Dr. Gonzalez-Reiche).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (HS#13-00981).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTo generate genome sequences, sequencing data were analyzed using a custom reference-based (MN908947.3) pipeline, https://github.com/mjsull/COVID_pipe. To analyze mismatches to diagnostic target PBSs, genome sequences were processed using a custom Unix-code https://github.com/AceM1188/SACOV_primer-probe_analyses. SARS-CoV-2 sequencing read data for all study genomes were deposited in GISAID [www.gisaid.org] (accessions pending). http://www.gisaid.org